Contribute Try STAT+ Today

The Food and Drug Administration’s surprise decision to reject the company’s Duchenne drug Vyondys 53 on Monday is another twist in the crazy, never-boring Sarepta Therapeutics story.

You can read more about the FDA’s denial of Vyondys 53 here, but read on for some additional thoughts, analyses, and lingering questions for investors trying to figure out what it all means for Sarepta moving forward.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Sarepta’s lack of foresight in planning for needing more data since 2016 is going to majorly impact this company’s ability to perform. Not only are they behind on follow up data with Exondys 51, they also had the hubris to think they could get accelerated approval with less data with Vyondys 53? It’s no wonder FDA rejected this drug.

    If what Adam says is right, they now have to rely on their internal pipeline almost completely for growth. No company with late phase assets is going to want to do a deal with these guys for bio bucks, so they have to rely on their current pipeline to get anything done or pay through the nose upfront for anything later stage.

    All around bad for investors and especially bad for patients and their families. This company should have been much more responsible with the resources it was given over the years to build a credible rare disease franchise.

Comments are closed.